Therapeutic Anti-CD9 Antibody

A method for at least in part treating or preventing a disorder associated with CD9-expressing cells, comprising administering to an individual in need thereof a therapeutically effective amount of an antibody or functional part or functional equivalent that comprises:

• a heavy chain CDR1 sequence that has at least 80% sequence identity with the sequence DYAMH (SEQ ID NO:2), and
• a heavy chain CDR2 sequence that has at least 80% sequence identity with the sequence GISWNSGSIVYADSVKG (SEQ ID NO:4), and
• a heavy chain CDR3 sequence that has at least 80% sequence identity with the sequence AVSGYYPYFDY (SEQ ID NO:6), and
• a light chain CDR1 sequence that has at least 80% sequence identity with the sequence KSSQSVLYSSNNKNYLG (SEQ ID NO:8), and
• a light chain CDR2 sequence that has at least 80% sequence identity with the sequence WASTRES (SEQ ID NO:10), and
• a light chain CDR3 sequence that has at least 80% sequence identity with the sequence QQYYTTP (SEQ ID NO:12);
• or administering to said individual a nucleic acid molecule or functional equivalent encoding said antibody or functional part or functional equivalent, or a vector comprising said nucleic acid molecule or functional equivalent, or an isolated or recombinant cell comprising said nucleic acid molecule or functional equivalent, or a composition comprising said antibody or functional part or functional equivalent, or a composition comprising said nucleic acid molecule or functional equivalent, or a composition comprising said vector or said cell.